Core Insights - Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. reported a significant increase in revenue and net profit for the first half of 2025, with revenue reaching 353 million yuan, a year-on-year growth of 32.73% [1] - The net profit attributable to shareholders was 24.76 million yuan, reflecting a substantial increase of 54.99% compared to the previous year [1] - The company achieved a net profit of 20.16 million yuan after deducting non-recurring gains and losses, marking a remarkable growth of 115.02% from 9.38 million yuan in the same period last year [1] - The net cash flow from operating activities was 39.43 million yuan [1] Business Operations - Hongbo Pharmaceutical provides comprehensive services for new drug research and commercialization for global pharmaceutical companies [1] - The company has maintained continuous investment and progress across multiple technology platforms during the reporting period [1] - Key advancements were noted in solid-state chemistry technology and process safety evaluation technology, which support the safe scale-up of projects from small trials to commercial production [1] Future Outlook - The company aims to continue focusing on technological innovation and platform development to meet the growing demands of global pharmaceutical clients [2]
泓博医药2025年半年报：营收3.53亿元 同比增长32.73%